Patients with Hodgkin’s disease, which is either refractory or recurs after frontline chemotherapy with MOPP (mechlorethamine, vincristine, procarbazine, and prednisone), ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine), or both regimens, generally have a poor prognosis. High-dose chemotherapy with autologous marrow or stem cell rescue (ABMT) is now a widely used salvage strategy in these patients. Among salvage regimens is ASHAP (ASHAP (Adriamycin = doxorubicin, Solumedrol = methylprednisolone, High-dose Ara-C = cytosine arabinoside, and Platinum = cisplatinum) which appears to provide a similar response rate to that of other chemo regimens. A similar regimen, ESHAP, is more established but there are no comparative trials for most regimens in use for salvage.
B. J. Byrne and J. P. Gockerman Salvage Therapy in Hodgkin’s Lymphoma Oncologist, February 1, 2007; 12(2): 156 – 167.
E. Brusamolino and A. M. Carella Treatment of refractory and relapsed Hodgkin’s lymphoma: facts and perspectives
Haematologica, January 1, 2007; 92(1): 6 – 10.
J. Rodriguez, M.A. Rodriguez, L. Fayad, P. McLaughlin, F. Swan, A. Sarris, J. Romaguera, B. Andersson, F. Cabanillas, and F.B. Hagemeister ASHAP: A Regimen for Cytoreduction of Refractory or Recurrent Hodgkin’s Disease
Blood 93: 3632-3636.
Hänel M, Kröger N, Hoffknecht MM, Peters SO, Metzner B, Fiedler F, Braumann D, Schubert JC, Illiger HJ, Hänel A, Krüger WH, Zeller W, Weh HJ, Hossfeld DK, Zander AR. ASHAP–an effective salvage therapy for recurrent and refractory malignant lymphomas.Ann Hematol. 2000 Jun;79(6):304-11.